drug
as of 2026-07-01Oxytocin
oxytocin
MeSH D010121
at a glance
OTHER
Pre-approval / investigational in the US
24 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
OTHER
Indications
Investigational (via trials)
Placebo + Non Specific CounsellingSchizophreniaAutism Spectrum DisorderAutism Spectrum DisorderPlacebo + Social Skills TrainingOxytocin + Social Skills TrainingSocial CognitionSchizophreniaSchizophrenia Spectrum DisordersFunctional Magnetic Resonance Imaging (fMRI)Psychotic DisordersMagnetoencephalography (MEG)Psychotic DisordersSocial AnxietyEmotional IntelligenceOxytocin
Trials
24
Oxytocin-Augmented Group Psychotherapy for Patients With Schizophrenia - an Oxytocin-dose Comparison
NCT07265180—Recruiting
OXYMIND: Oxytocin-augmented Group Psychotherapy for Patients With Schizophrenia
NCT06136390—Completed
A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia
NCT03900754Phase 2Terminated
Neurobiological Effects of Oxytocin in Schizophrenia
NCT04177719—Unknown
The Association of Affective Resonance With Empathy Modulated by Negative Symptomatology and Oxytocin
NCT05247151—Completed
Effects of Oxytocin on Negative Symptoms and Social Cognition in Schizophrenia and Its Possible Mechanisms
NCT03662425—Completed
Adult Study Oxytocin - Behavioral
NCT02567032Early Phase 1Completed
Neurobiological Effects of Oxytocin in Schizophrenia - Imaging Study
NCT04158167—Completed
Antipsychotic Effects of Oxytocin
NCT01621737—Terminated
Dyad Oxytocin Study (DOS)
NCT02302209Phase 1Completed
Adult Study Oxytocin - fMRI
NCT02566356Early Phase 1Completed
Oxytocin as Adjunctive Treatment of Schizophrenia
NCT01568528Phase 2Completed
Oxytocin MEG Study
NCT02568709Early Phase 1Completed
Adult Oxytocin Study
NCT02577575Early Phase 1Completed
Effects of Oxytocin Nasal Spray on Social Affiliation
NCT00663039Phase 2Completed
Oxytocin as Adjunctive Therapy for Schizophrenia
NCT01699997Phase 2Completed
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
NCT01012167Phase 2Completed
Oxytocin Add on Study for Stable Schizophrenic Patients
NCT00506909—Terminated
Administrating Oxytocin to Treat Treatment Schizophrenia and Schizo-affective Patients
NCT01598623Phase 2Unknown
Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia
NCT01614093Phase 4Completed
Pharmacological Approach to Improve the Outcome of Social Cognition Training
NCT01517360Phase 1Completed
Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?
NCT01312272—Completed
Oxytocin and Social Cognition in Schizophrenia
NCT00884897Phase 2Completed
KOLs & investigators
12
Stephen R. Marder, MDKOL score 14
Kerem Böge, Prof.KOL score 9
Mark Weiser, MDKOL score 9
Deanna L. Kelly, Pharm.D., BCPPKOL score 5
Marco Zierhut, Dr.KOL score 5
Eric Hahn, PDKOL score 5
Erica J. Duncan, MDKOL score 5
L. Elliot Hong, M.D.KOL score 5
David J. Miklowitz, Ph.D.KOL score 5
Steven G Potkin, MDKOL score 5
Josh D Woolley, MD/PhDKOL score 5
William R. McFarlane, M.D.KOL score 5
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
trial
indication
indication
indication
indication
indication
KOL
Stephen R. Marder, MD
personKOL score 14
Kerem Böge, Prof.
personKOL score 9
Mark Weiser, MD
personKOL score 9
Deanna L. Kelly, Pharm.D., BCPP
personKOL score 5